Hematology & Medical Oncology
Fadlo R. Khuri, M.D.
Department Chair, Hematology and Medical Oncology
Dr. Khuri is Professor and Chairman of the Department of Hematology and Medical Oncology in the Emory School of Medicine. He is a Professor of Otolaryngology, Medicine, and Pharmacology, and holds the Roberto C. Goizueta Distinguished Chair for Cancer Research. In addition to his role as Deputy Director of the Winship Cancer Institute, Dr. Khuri serves as co-leader of Winship’s Discovery and Developmental Therapeutics Resarch Program.
Dr. Khuri earned his bachelor's degree from Yale University, in New Haven, CT, and his doctoral degree from Columbia University, College of Physicians and Surgeons, in New York, NY. He completed his residency in internal Medicine at the Boston City Hospital, Boston University School of Medicine. He then completed a fellowship in Hematology and Medical Oncology at the New England Medical Center, Tufts University School of Medicine. He is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology and is an active member of the American Association for Cancer Research, and the American Society of Clinical Oncology. He was on faculty at the University of Texas M.D. Anderson Cancer Center from 1995-2002 prior to joining Emory University.
Dr. Khuri's clinical interests include thoracic and head and neck oncology. His research interests include development of molecular, prognostic, therapeutic, and chemopreventive approaches to improve the standard of care for patients with tobacco related cancers. His laboratory is investigating the mechanism of action of signal transduction inhibitors in tobacco related cancers. Dr. Khuri is the recipient of numerous awards, including being listed among America's Top Doctors and the Marquis Who's Who in the World. He is the recipient of a Georgia Cancer Coalition Distinguished Clinical Scholar Award, serves on the editorial boards of 7 journals, including the Journal of Clinical Oncology, Clinical Cancer Research and Cancer, and has published over 100 peer reviewed articles in elite journals including Nature Medicine, Journal of the National Cancer Institute, Cancer Research and the Journal of Clinical Oncology. He has been the recipient of competitive, peer-reviewed federal grant support from the National Cancer Institute, Department of Defense, and American Cancer Society over the last decade.
View an interview with Dr. Khuri explaining the Winship difference for lung cancer patients